Pharmaceutical Technology

MAY 24, 2023

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Intouch Solutions

OCTOBER 13, 2023

They can include the conditions in which people are born, live, learn, work, play, worship, and age 1,2 — as well as factors like economic policies and systems, development agendas, social norms, social policies and political systems. Pharmaceutical companies can develop and disperse these materials.

Pharma Companies 105

Pharma Companies Clinical Trials Clinical Trials Genetics 105

XTalks

JANUARY 15, 2024

From the continuing trend of the rapid adoption of AI tools to the growing use of real-world evidence (RWE) in regulatory decision-making and a focus on enhancing data integrity, find out how clinical trials will evolve in 2024 to shape the future of medical research. percent from 2023 to 2033.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Clinical Research 105

pharmaphorum

MARCH 28, 2022

Noga Yerushalmi, investment director at M Ventures (the venture arm of Merck), tells us how AION Labs was formed and aspires to help ease the pharma industry’s shared challenges by offering its vast resources a new start-up. Then, a development stage or optimisation stage occurs. The partnership. ” The Application .

Pharma Companies 97

Pharma Companies Antibody Protein Development 97

Pharmaceutical Technology

MARCH 6, 2023

Incannex Healthcare has collaborated with New Jersey-based pharma company Catalent for the development and manufacturing of a cGMP-grade psilocybin drug product for clinical trials and potential commercial use. Catalent will develop the formulation and produce the required data for regulatory filings.

Manufacturing 264

Manufacturing Clinical Trials Clinical Trials Production 264

Drug Discovery World

DECEMBER 7, 2022

The programme is aimed at organisations seeking to develop leadership and mentoring skills and promote diversity in the life sciences work environment. We are excited to open up the waitlist for the next stage, and encourage people from other backgrounds to get involved, including our tech company members.” .

Pharma Companies 52

Pharma Companies Life Science Regulation Scientist 52

pharmaphorum

MAY 26, 2022

Within pharma and healthcare, where greater representation has been proven to lead to better health outcomes for all patients and the pharmaceutical companies developing medicines, change is also happening. In recent years this has seen diversity, equity, and inclusion (DEI) become a big focus for industries to get right.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Medicine 130

XTalks

SEPTEMBER 5, 2023

Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

pharmaphorum

NOVEMBER 3, 2021

The development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium of pharma companies has just identified a new one for atopic dermatitis. The post Pharma group will develop ‘digital endpoint’ for atopic dermatitis appeared first on.

Development 70

Development Pharma Companies Trials Clinical Trials 70

Camargo

NOVEMBER 11, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Still, navigating such patent issues during drug development can be difficult, and Camargo can assist in finding a safe course. Ken Phelps.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

JANUARY 17, 2022

The adoption of decentralised activities was a major factor in allowing clinical trials to continue during the early stages of the pandemic. Ben Hargreaves examines whether this adoption looks set to become a permanent feature of clinical trials moving into the future, rather than just supplying the tools to a temporary need.

Trials 101

Trials Clinical Trials Clinical Trials Clinical Research 101

World of DTC Marketing

JANUARY 11, 2022

As HCPs get more digitally savvy, pharma marketers should understand that engaging physicians through channels and time of their preference with content relevant to the individual customer. Key findings: 77% of HCPs use digital channels primarily for personal learning and development.

Pharma Companies 235

Pharma Companies Sales Marketing Clinical Trials 235

Pharmaceutical Technology

MARCH 20, 2023

Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinical trials. Clinical trials data for Africa Globally, research has found that 62.2% being African American, 3.4%

Clinical Trials 130

Clinical Trials Clinical Trials Trials Clinical Supply Chain 130

Drug Discovery World

JANUARY 26, 2024

Dr Bentwich will present on ‘ How artificial intelligence and patient-on-a-chip are improving drug development ’ on Tuesday 6 February at 3pm. His presentation will explore the impact of Quris-AI’s Bio-AI platform in the field of drug development.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Genome 52

Pharmaceutical Technology

APRIL 13, 2023

The company is aiming to refocus its efforts on its core therapeutic areas and current late-stage programmes such as the oral TYK2 inhibitor TAK-279, which is under development for several autoimmune disorders.

Gene Therapy 243

Gene Therapy Marketing Gene In-Vivo 243

Outsourcing Pharma

SEPTEMBER 4, 2023

The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.

Pharma Companies 78

Pharma Companies Trials Drugs Development 78

Pharmaceutical Technology

JANUARY 16, 2023

Moreover, Insilico Medicine’s INS018_055, an AI-designed candidate, has produced positive topline results in its Phase I clinical trial for idiopathic pulmonary fibrosis (IPF) treatment. In addition to collaborating with AI-technology providers, pharma companies are also engaging in vertical integration.

Big Data 303

Big Data Pharma Companies Clinical Trials Clinical Trials 303

Drug Discovery World

OCTOBER 18, 2022

A working group has been created to measure and compare the carbon footprint of centralised (traditional site-based) and decentralised clinical trials. The Clinical Trials Environmental Impact Community of Interest (CoI) was started by Pistoia Alliance member, Syneos Health. Growing pressure on life sciences.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Life Science 52

pharmaphorum

AUGUST 24, 2022

Diversity in clinical trials is a “scientific imperative”, but how can industry bridge the gap between “why” and “how”? Removing barriers to clinical trial participation for underserved groups is an essential part of addressing health inequalities. Clinical trial participation, she went on, was vital. Why, not how.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Development 95

Drug Discovery World

JANUARY 26, 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. billion showed the pharma giant taking further steps into the oncology market and developing its speciality medicines vaccines portfolio.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

JULY 8, 2022

The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) have gained traction as technology, infrastructure and knowledge have evolved to support their use. Source: Izmailova et al, 2017.

Clinical Trials 75

Clinical Trials Clinical Trials Trials Regulation 75

pharmaphorum

AUGUST 12, 2022

An at-home electroencephalogram (EEG) headset used alongside game-like cognitive tasks developed by UK company Cumulus Neuroscience has been shown to be more effective than lab-based EEG monitoring in a clinical trial. The post Cumulus’ gamified dry EEG system tops lab monitoring in trial appeared first on.

Trials 94

Trials Clinical Trials Clinical Trials FDA Approval 94

pharmaphorum

MAY 27, 2022

This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical trials. The same principles are increasingly being applied to clinical trials to improve diversity, mitigate bias, and reinforce inclusion in clinical trials.

Clinical Trials 78

Clinical Trials Clinical Trials Trials Packaging 78

Outsourcing Pharma

OCTOBER 24, 2023

Clinical stage pharma company PharmaKure believe their combined drug targeting amyloid deposits associated with Alzheimerâs Disease can bring quality of life to patients.

Pharma Companies 52

Pharma Companies Trials Drugs Clinical Development 52

pharmaphorum

NOVEMBER 11, 2022

The lack of diversity in clinical trials has been a topic of debate for decades, but was thrust into the spotlight as the impact of the pandemic on poorer, less educated and ethnically diverse populations became even more apparent. Zeroing in on trials with only US sites is a little more encouraging, but the trends are in the same direction.

Clinical Trials 78

Clinical Trials Clinical Trials Trials Pharma Companies 78

pharmaphorum

JANUARY 24, 2022

The UK scientists that ran one of the largest trials of experimental COVID-19 drugs have formed a non-profit company that will apply the methodology to other disease areas – with $6.8 ” Those trials also need to be large, involve a diverse range of individuals, and able to be run at reduced cost, said Landray. .

Trials 80

Trials Drugs Clinical Trials Clinical Trials 80

Camargo

MARCH 9, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The FDA revealed that pharma companies are not forthcoming when they publicly disclose the reasons behind a refuse-to-file (RTF) letter from the Agency.

Development 146

Development Manufacturing Drugs Production 146

Drug Discovery World

DECEMBER 12, 2022

Biometrics contract research organisation (CRO) Phastar has joined Lean Life Science’s Oncology Development Programme (ODP2). . The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies. .

Development 52

Development Drugs Pharma Companies Clinical Trials 52

pharmaphorum

MARCH 12, 2021

COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement. Speakers at the NIHR’s recent virtual event for the pharma industry discussed best practices for bringing patient insights into research.

Trials 116

Trials Research Pharma Companies Clinical Trials 116

pharmaphorum

FEBRUARY 1, 2022

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?

Clinical Trials 87

Clinical Trials Clinical Trials Trials Engineer 87

pharmaphorum

SEPTEMBER 7, 2022

Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. The industry’s application of mRNA techniques during the pandemic led to the fastest vaccine development in history. But our drug development processes are not perfect. But embedded bias intersects these.

Clinical Trials 89

Clinical Trials Clinical Trials Trials Genetics 89

pharmaphorum

FEBRUARY 11, 2021

Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research.

Clinical Trials 89

Clinical Trials Clinical Trials Trials Clinical Research 89

pharmaphorum

FEBRUARY 4, 2022

Last year, Bayer launched a project to explore the use of artificial intelligence in clinical trials, working with Finland’s Aalto University to find ways to use the technology to support decentralised trials and streamline the testing process.

Trials 67

Trials Clinical Trials Clinical Trials Pharma Companies 67

XTalks

MAY 11, 2023

Clinical trials are essential for the development of new treatments for rare diseases, but they can be complex and challenging to execute. Patient input is a crucial component of rare disease clinical trials, as it can provide valuable insights into the patient experience and inform decisions about study design and implementation.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. developed dementia over the subsequent two years (vs. Notably, among over-65s who had had Covid-19, 4.5%

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

SEPTEMBER 2, 2020

But many patients still do not respond to therapies such as Merck & Co’s anti PD-1 therapy Keytruda (pembrolizumab), or go on to develop progressive disease, and pharma companies are looking for new second-line therapies. A total of 40 patients are planned to be enrolled.

Trials 103

Trials RNA Pharma Companies Clinical Trials 103